Zymeworks Stock News

The trading price of Zymeworks Inc. (NYSE:ZYME) closed lower on Monday, December 13, closing at $15.80, -1.68% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

SVB Leerink upgraded shares of Zymeworks (NYSE:ZYME) from a market perform rating to an outperform rating in a research note released on Friday, Analyst Price Targets reports. Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Zymeworks from a buy rating to a hold rating in a […] The post SVB Leerink Upgrades Zymeworks (NYSE:ZYME) to “Outperform” appeared first on ETF Daily News .

Shares of Zymeworks Inc. (NYSE:ZYME) reached a new 52-week low during trading on Monday . The company traded as low as $15.65 and last traded at $15.84, with a volume of 27711 shares. The stock had previously closed at $16.07. ZYME has been the subject of a number of recent research reports. SVB Leerink upgraded []

SVB Leerink upgraded shares of Zymeworks (NYSE:ZYME) from a market perform rating to an outperform rating in a research note issued to investors on Friday, Price Targets.com reports. A number of other brokerages have also commented on ZYME. Raymond James lowered Zymeworks from a strong-buy rating to an outperform rating and set a $74.00 price []

Taylor Wealth Management Partners raised its stake in Zymeworks Inc. (NYSE:ZYME) by 1.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 66,968 shares of the companys stock after buying an additional 686 shares during the period. Taylor Wealth Management Partners []

Raymond James cut shares of Zymeworks (NYSE:ZYME) from a strong-buy rating to an outperform rating in a report issued on Thursday morning, The Fly reports. Several other equities research analysts also recently issued reports on the stock. Jefferies Financial Group began coverage on shares of Zymeworks in a research note on Wednesday, October 6th. They []

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-Operative Inflammation EyePoin

Zymeworks Inc. (NYSE:ZYME) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $17.63 and last traded at $17.83, with a volume of 5775 shares trading hands. The stock had previously closed at $18.49. ZYME has been the subject of several research analyst reports. HC Wainwright restated a […]

Equities analysts expect that Zymeworks Inc. (NYSE:ZYME) will announce earnings per share (EPS) of ($1.10) for the current quarter, Zacks reports. Five analysts have issued estimates for Zymeworks earnings, with the lowest EPS estimate coming in at ($1.25) and the highest estimate coming in at ($0.92). Zymeworks reported earnings per share of ($0.74) in the []

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Thrivent Financial for Lutherans increased its holdings in shares of Zymeworks Inc. (NYSE:ZYME) by 2.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 322,364 shares of the companys stock after buying an additional 7,547 shares during the quarter. Thrivent Financial for []

In last trading session, Zymeworks Inc. (NYSE:ZYME) saw 0.48 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $18.49 trading at -$1.75 or -8.65% at ring of the bell on the day assigns it a market valuation of $841.66M. That closing price of ZYME’s stock is at … Does Zymeworks Inc. (NYSE:ZYME) Look Expensive At $18.49? Here’s How To Know. Read More »

Vigilare Wealth Management acquired a new stake in Zymeworks Inc. (NYSE:ZYME) during the third quarter, according to its most recent filing with the SEC. The firm acquired 10,200 shares of the companys stock, valued at approximately $296,000. A number of other institutional investors have also added to or reduced their stakes in ZYME. Cutler Group []